---
title: "Suzhou Ribo Advances PCSK9 siRNA Drug RBD7022 Into Phase III Trial in China"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/277382303.md"
description: "Suzhou Ribo Life Science Co., Ltd. has announced the advancement of its siRNA therapy, RBD7022, into Phase III clinical trials in China, in collaboration with Qilu Pharmaceutical Co., Ltd. This therapy targets PCSK9 for hyperlipidemia treatment and represents a significant step towards offering a new cholesterol-lowering option. The company emphasizes that while this marks progress in its cardiovascular portfolio, successful development and commercialization are not guaranteed, highlighting the clinical and regulatory risks involved."
datetime: "2026-03-02T00:38:36.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/277382303.md)
  - [en](https://longbridge.com/en/news/277382303.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/277382303.md)
---

# Suzhou Ribo Advances PCSK9 siRNA Drug RBD7022 Into Phase III Trial in China

### Claim 50% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

The latest update is out from Suzhou Ribo Life Science Co., Ltd. Class H ( (HK:6938) ).

Suzhou Ribo Life Science Co., Ltd. announced that its independently developed RBD7022 Injection, a small interfering RNA (siRNA) therapy targeting PCSK9 for the treatment of hyperlipidemia, has completed public registration for a Phase III clinical trial in China through its collaborator Qilu Pharmaceutical Co., Ltd. The program builds on an existing agreement granting Qilu exclusive rights to develop, manufacture, and commercialize RBD7022 in mainland China, Hong Kong, and Macau, marking a key milestone in bringing a novel cholesterol-lowering option closer to market, though the company cautions that successful development and commercialization are not guaranteed.

The initiation of the Phase III trial underscores Suzhou Ribo’s push to advance its cardiovascular portfolio and positions the company more prominently within China’s growing market for innovative lipid-lowering therapies. If successful, RBD7022 could offer a new treatment alternative for patients with hypercholesterolemia at risk of cardiovascular disease, potentially strengthening the company’s competitive standing and deepening its strategic collaboration with Qilu Pharmaceutical, while investors are reminded of the inherent clinical and regulatory risks.

**More about Suzhou Ribo Life Science Co., Ltd. Class H**

Suzhou Ribo Life Science Co., Ltd. is a biotechnology company based in the People’s Republic of China, focused on the research and development of RNA interference (siRNA) therapeutics. The group develops innovative drugs targeting major chronic diseases, with a particular emphasis on cardiovascular and metabolic disorders in the Chinese and broader Greater China markets.

**Average Trading Volume:** 990,300

**Current Market Cap:** HK$11.68B

### Related Stocks

- [06938.HK](https://longbridge.com/en/quote/06938.HK.md)

## Related News & Research

- [Suzhou Ribo Advances CAD siRNA Drug With EMA Phase II Filing](https://longbridge.com/en/news/287870663.md)
- [Ribo Announces Phase 2 Clinical Trial Submission to EMA, Further Advancing siRNA Therapeutics in Thromboembolic Disease](https://longbridge.com/en/news/287850086.md)
- [Lilly reports positive interim results from Heart-2 trial of VERVE-102](https://longbridge.com/en/news/287619982.md)
- [18:00 ETNEW VIRTUAL COMMUNITY ADVISORY BOARD SEEKS YOUNG ADULTS WITH EXPERIENCE IN THE CRIMINAL LEGAL SYSTEM](https://longbridge.com/en/news/287977226.md)
- [12:00 ETEclipsebio Expands eCOMPASS™ Platform with eSENSE Break™ to Map RNA Fragmentation at Nucleotide Resolution](https://longbridge.com/en/news/288302490.md)